Ajanta Pharma, a Rs.1,450 crore plus pharma major, has posted satisfactory performance during the second quarter ended September 2015. Its consolidated net profit increased by 20.5 per cent to Rs.99.96 crore from Rs.83 crore in the same period of last year. EBIDTA increased by 19.2 per cent to Rs.156.70 crore from Rs.131.50 crore. Its consolidated net sales also moved up by 18.6 per cent to Rs.434 crore from Rs.366 crore. With significant jump in profits, its EPS went up to Rs.11.37 from Rs.9.44 in the last period.
Yogesh M Agrawal, managing director, said, “Despite challenges posed by currency devaluation's in most of the emerging markets, we have delivered sound performance in these geographies. We continue to post above industry growth in India market with utmost focus on brand building. To accelerate product filings, we are increasing spend levels in R&D which ensures sustained growth in future.”
The branded business in India achieved a growth of 20 per cent to Rs.123 crore, with total India revenue including Institution being Rs.131 crore. It achieved strong growth of 39 per cent in cardiology, 41 per cent in ophthalmology, 17 per cent in dermatology and 44 per cent in pain management.
Its emerging market business also improved by 20 per cent with sale of Rs.301 crore. Africa contributed Rs.175 crore, followed by Asia Rs.124 crore and Latin America Rs.3 crore. The company increased its R&D investments which reached at Rs.26 crore and worked out to 6 per cent of net sales. It received approval for 5 ANDAs and another 20 ANDAs are in various stages of approval with US FDA,
For the first half ended September 2015, Ajanta's consolidated net sales increased by 20.5 per cent to Rs.820 crore from Rs.681 crore and its net profit moved up by 28.8 per cent to Rs.184 crore from Rs.143 crore. EBIDTA worked out to 33 per cent of revenue. Indian branded business improved by 19 per cent to Rs.251 crore. Further, the sales in emerging market went up by 21 per cent to Rs.540 crore. Africa contributed Rs.322 crore and improved y 28 per cent. The company has pipeline of over 1,700 products under registration paving the way for sustained growth in international market. Its R&D expenditure increased to Rs.45 crore from Rs.30 in the last period.
For last 5 years, company has posted healthy performance with its consolidated revenue growing at 31 per cent CAGR of and net profit at 57 per cent CAGR.